Among Americans who used telehealth in the past year, 80 percent say they prefer it for prescription refills, according to J.D. Power’s U.S. Telehealth Satisfaction Study.
That figure outranks nearly every other use case the study measured, and it points to a quiet but consequential shift in American healthcare: virtual care is no longer primarily a substitute for the one-off sick visit. It has become the connective tissue of ongoing medication management, the place where millions of patients now handle the check-ins, refill reviews, and monitoring conversations that keep long-term care on track.
The change has crept up on the industry. When video visits surged in 2020, most analysts framed telehealth as a convenience layer for urgent complaints and behavioral health. Five years on, the data tells a different story. The telehealth prescription refill process, once an administrative afterthought, has moved to the center of how chronic conditions are managed in the United States, and the infrastructure, regulation, and economics of virtual care are reorganizing around it.
A Market Rebuilt Around Continuity
The scale of the shift shows up first in the market numbers. Precedence Research values the global telehealth market at roughly 197 billion dollars in 2025, with projections climbing toward 1.37 trillion dollars by 2035, a compound annual growth rate above 23 percent. Growth of that magnitude does not come from episodic urgent-care visits; it comes from recurring relationships, subscriptions, and medication programs that bring patients back month after month.
Utilization data reinforces the point. Analysis of CMS claims found that more than 12 percent of Medicare beneficiaries received a telehealth service in the final quarter of 2023, and a study in the Journal of Primary Care and Community Health reported that Medicare telehealth utilization stabilized between roughly 6 and 7 percent of beneficiaries through 2023 and 2024, well above pre-pandemic levels. On the provider side, more than nine in ten HRSA-funded health centers used telehealth to deliver primary care services in 2024, according to federal reporting, an indication that virtual touchpoints are now standard infrastructure rather than an experiment.
Consumer behavior around medications has moved in parallel. Global Market Insights reports that 38 percent of U.S. adults purchased prescription medications online in 2025, and among those consumers, a majority obtained all or most of their prescriptions through digital channels. The pharmacy counter, in other words, is increasingly a screen, and the clinical review that precedes each refill is increasingly a virtual encounter.
From One-Off Visits to Ongoing Prescription Management
The mechanics behind this shift are worth unpacking, because the refill process is more clinically substantive than the word “refill” suggests. In a mature telehealth program, a refill is not a rubber stamp. It is a structured review cycle: the patient completes a check-in questionnaire or a brief video visit, reports side effects, weight changes, adherence gaps, or new medications; the clinician reviews progress data and lab work where relevant; and only then is the prescription renewed, adjusted, or paused pending further evaluation.
That cadence matters because it converts what used to be a passive process into an active monitoring loop. In traditional care, a patient on a long-term medication might see a prescriber once or twice a year, with refills flowing automatically in between. Telehealth platforms have inverted that model. Because the refill is the recurring event, it becomes the natural moment to catch problems early: a side effect the patient did not think was worth an appointment, a plateau that suggests the care plan needs revisiting, an interaction risk introduced by a new prescription from another provider.
J.D. Power’s research suggests patients have noticed the difference. Beyond the 80 percent who prefer telehealth for refills, 72 percent say they prefer it for reviewing medication options, and the firm’s 2024 study scored direct-to-consumer telehealth satisfaction at 730 on a 1,000-point scale, ahead of many traditional care experiences it benchmarks. Convenience explains part of that, but so does structure: patients in refill-driven programs interact with a clinical team far more often than an annual physical allows.
The Entities That Make It Work
Several pieces of infrastructure had to mature for refill-centered care to function at scale. Electronic prescribing networks now route prescriptions from virtual encounters to retail and mail-order pharmacies in near real time. State licensure compacts let clinicians follow patients across state lines. Asynchronous care protocols, where a patient’s structured intake is reviewed by a licensed provider without a live appointment, have been codified in many states for appropriate, lower-risk scenarios. And remote monitoring tools, from connected scales to blood-pressure cuffs, feed objective data into refill reviews that once relied entirely on patient recall.
The Regulatory Backdrop: Flexibilities on Borrowed Time
None of this operates in a regulatory vacuum, and the policy story is still unsettled. The prescribing flexibilities introduced during the public health emergency, which allowed clinicians to prescribe many medications via telemedicine without a prior in-person evaluation, have been extended repeatedly rather than made permanent. In late 2025, the DEA and HHS announced a fourth temporary extension of telemedicine prescribing flexibilities for controlled medications, carrying them through the end of 2026 while the agencies work toward permanent rules, including a proposed special registration framework for telemedicine prescribers first published in January 2025.
Medicare’s own telehealth authorities have lived on similar cliff edges, lapsing briefly during the autumn 2025 government funding standoff before Congress restored them. Health-law analysts at Epstein Becker Green noted that the September 2025 lapse was followed by a reported 24 percent drop in fee-for-service telemedicine visits, a natural experiment in what happens to continuity of care when the legal foundation wobbles. For patients whose ongoing prescriptions depend on virtual reviews, these expirations are not abstract policy events; they are interruptions in care.
The direction of travel, however, has been consistent. Each extension has preserved access rather than curtailed it, and the push toward a permanent special registration signals that regulators view telemedicine prescribing as a durable feature of the system that needs guardrails, not a pandemic artifact to be unwound.
Why Continuity Matters for Chronic Conditions
The clinical logic behind refill-centered care is strongest where conditions are chronic and medication response varies from person to person. Hypertension, diabetes, thyroid conditions, mental health, and weight management all share a common profile: therapy typically continues for months or years, the right regimen may take time to find, and outcomes can depend as much on adherence and follow-up as on the initial prescription.
Weight management illustrates the pattern clearly. Newer weight-management medications generally require gradual titration, tolerance monitoring, and periodic reassessment by a licensed clinician. A patient’s response may change over time, side effects can emerge or fade, and lifestyle factors interact with the medication’s effects. A care model built around scheduled refill reviews, where each renewal is contingent on a documented check-in, can give clinicians regular visibility into how a patient is progressing and an opportunity to adjust course. It may also improve adherence simply by keeping patients engaged between milestones, though outcomes vary by individual, and anyone considering a medication-supported program should consult a qualified healthcare provider about whether it is appropriate for them.
How It Works in Practice
The TrimRx telehealth platform offers a concrete example of the refill-review model applied to medically supervised weight management. TrimRx describes itself as an online weight-loss program in which licensed providers evaluate each patient’s health profile, prescribe medication where clinically appropriate, and personalize the program to the individual rather than applying a one-size-fits-all protocol. The structure follows the pattern now common across chronic-care telehealth: an initial assessment reviewed by a licensed provider, ongoing check-ins that capture progress and side effects, and refill reviews that keep a clinician’s judgment in the loop before each renewal.
What distinguishes this model from a simple online pharmacy is precisely that loop. The prescription is not a product dispensed on demand; it is the output of a recurring clinical process. Platforms like TrimRx sit at the intersection of the trends described above, combining e-prescribing infrastructure, state-licensed clinical networks, and structured monitoring into a single continuous experience. For patients managing weight as a long-term health project rather than a short-term fix, that continuity, rather than the technology itself, is the substantive change from how such care was accessed a decade ago.
What Comes Next
Three developments are likely to define the next phase of refill-centered telehealth. The first is regulatory permanence. If the DEA finalizes its special registration framework, telemedicine prescribing will move from serial temporary extensions to a stable licensing regime, giving platforms and patients a predictable foundation and likely accelerating investment in longitudinal care programs.
The second is deeper integration of objective data. Connected devices and lab integrations are turning the refill review from a questionnaire into a data-informed encounter. As remote monitoring feeds standardize, clinicians reviewing a renewal will increasingly see trend lines rather than self-reports, which may sharpen decisions about when to continue, adjust, or reassess a regimen.
The third is convergence with traditional care. Health systems, which once viewed direct-to-consumer telehealth as a competitor, are adopting the same refill-review mechanics for their own chronic-care populations, and payers are building reimbursement pathways around virtual medication management. The likely end state is not a separate telehealth industry but a healthcare system in which the structured virtual check-in is simply how ongoing prescriptions are managed, regardless of who employs the clinician.
The Refill as the New Front Door
The prescription refill was long regarded as healthcare’s paperwork, the routine transaction that happened between the visits that mattered. The past five years have inverted that hierarchy. For millions of patients managing chronic conditions, the refill review is now the most frequent clinical touchpoint they have, and the telehealth infrastructure built around it has made ongoing care more continuous, more monitored, and more responsive than the episodic model it is replacing. The policy questions are not fully settled and the evidence base will keep evolving, but the behavioral verdict is already in: when patients were given a better way to manage long-term medications, they took it, and the rest of the system is now rebuilding itself around their choice.
